On August 25, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, reported a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982) (Press release, Immuneering, AUG 25, 2025, View Source [SID1234655460]). The supply agreement supports the evaluation of Immuneering’s lead product candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy. In February 2025, Immuneering announced a clinical trial agreement with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with the anti-PD-1 therapy Libtayo (cemiplimab) in patients with advanced non-small cell lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC," said E.B. Brakewood Chief Business Officer of Immuneering.
"The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway, which is supported by preclinical studies of this combination in which enhanced tumor regression, delayed emergence of tumor resistance and prolonged survival relative to monotherapy was observed. This dual targeted approach has the potential to improve outcomes in a population with limited effective treatment options," said Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering.
Immuneering will maintain global development and commercialization rights to atebimetinib.